Absci is trading at $11.28, up 6.72%, with the move most consistent with biotech-sector strength, though its exact cause remains unconfirmed.
- No clear new company-specific catalyst was identified for October 28; Absci’s October 27 announcement concerned routine participation in upcoming investor conferences.
- XBI was up 2.18% amid positive clinical-trial and regulatory news across the sector.
- Broader indexes were only modestly higher.